<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01566188</url>
  </required_header>
  <id_info>
    <org_study_id>2010/010 HP</org_study_id>
    <nct_id>NCT01566188</nct_id>
  </id_info>
  <brief_title>Vascular Impact of Omega-3 in Metabolic Syndrome</brief_title>
  <acronym>CARDIOMEGA</acronym>
  <official_title>Cardiovascular Impact of Omega-3 Dietary Supplement From Vegetal Origin in Hypertension Associated With Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aims of the present project are to investigate the impact of a nutritional
      approach based on omega-3 from vegetal origin on vascular function in hypertension associated
      with metabolic syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brachial artery flow-mediated dilatation</measure>
    <time_frame>6 months after omega-3 supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Aortic stiffness</measure>
    <time_frame>6 months after omega-3 supplementation</time_frame>
    <description>carotid-to-femoral pulse wave velocity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>omega-3 from vegetal origin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>omega-3 from vegetal origin</intervention_name>
    <description>6 months of supplementation with omega-3 from vegetal origin</description>
    <arm_group_label>omega-3 from vegetal origin</arm_group_label>
    <other_name>Cyclodextrin/Camelin oil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>6 months of supplementation with placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Cyclodextrin/Starch</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female and male patients with treated essential hypertension (blood pressure
             values&lt;140/90 mmHg under antihypertensive treatment).

          -  Presence of at least two of the following criteria of the metabolic syndrome:
             abdominal girth &gt;102 cm in men or &gt;88 cm in women, HDL-C&lt;0.4 g/L in men or &lt;0.5 g/L in
             women, fasting triglyceride &gt;1.5 g/L (or specific treatment for these lipid
             abnormalities), fasting glucose &gt;1.10 g/L.

        Exclusion Criteria:

          -  Secondary hypertension, myocardial infarction, coronary artery disease,
             cerebrovascular disease, stroke or transient ischemia, cardiac failure, diabetes (or
             fasting glucose&gt;1.26 g/L) or renal failure (MDRD &lt; 50 ml/min)

          -  Severe hypercholesterolemia (total cholesterol &gt; 2.5 g/l), alcohol or drug abuse,
             toxicomania, or clinically significant abnormalities in other current biological
             parameters.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robinson Joannides, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rouen University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mahes Hospital</name>
      <address>
        <city>Fleury-MÃ©rogis</city>
        <zip>91700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Pompidou European Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rouen University Hospital</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rangueil University Hospital</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 29, 2012</study_first_posted>
  <last_update_submitted>September 1, 2014</last_update_submitted>
  <last_update_submitted_qc>September 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Metabolic Syndrome X</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

